COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol.24, no.3, pp.400-408, 2021 (SCI-Expanded)
Background: Bronchial asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic diseases. Roflumilast is a novel, potent, selective, and long-acting phosphodiesterase 4 (PDE-4) inhibitor for the treatment of bronchial asthma and COPD. It has anti-inflammatory effects, and it has been shown to reduce exacerbations and improve pulmonary function in patients with COPD. Although there have been some other analytical methodologies reported for the determination of roflumilast in pharmaceutical dosage forms, there has not yet been any electrochemical methodology proposed for determination of this unique active pharmaceutical ingredient in its dosage forms.